Key Highlights
- Marker Therapeutics has been awarded a $16.2 million Product Development Research grant from CPRIT.
- The funding will support the Phase 2 APOLLO study of MT-601 (neldaleucel) for patients with large B-cell lymphoma who relapse after CAR-T therapy.
- Phase 1 results showed a 66% objective response rate and 50% complete response rate among 12 evaluable patients, with responses lasting up to 24 months.
- CPRIT received 207 applications for this funding cycle and awarded a total of $74.3 million to 12 projects.
Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies, has been awarded a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The funding will support advancement of the company's lead investigational therapy, MT-601 (neldaleucel), in the planned Phase 2 APOLLO study for patients with relapsed or refractory large B-cell lymphoma (LBCL) following CD19-directed CAR-T cell treatment.
The CPRIT Product Development Research program is a competitive initiative established by the State of Texas to advance innovative cancer therapies toward commercialization. For this funding cycle, CPRIT received 207 applications and awarded $74.3 million to 12 projects.
What Did Phase 1 Results Show?
The CPRIT award builds on Phase 1 APOLLO study results reported in August 2025. Among 12 evaluable patients with non-Hodgkin lymphoma, the study showed a 66% objective response rate and a 50% complete response rate. Durable responses were observed, including responses lasting up to 24 months at the data cutoff. MT-601 demonstrated a favorable safety profile across evaluated dose levels, with no dose-limiting toxicities or immune-effector cell-associated neurotoxicity syndrome (ICANS).
CEO Juan Vera stated that the CPRIT award provides meaningful external recognition of the company's differentiated MAR-T cell approach and substantial non-dilutive funding to support the Phase 2 study. Updated clinical results are expected later this year.
What Is MT-601 and How Does It Differ From CAR-T?
MT-601 is a MAR-T cell product that utilizes a non-genetically modified approach targeting six different tumor antigens upregulated in lymphoma cells: Survivin, PRAME, WT-1, NY-ESO-1, SSX-2, and MAGEA-4. This multi-antigen approach differs from CAR-T therapies, which typically target a single antigen such as CD19. By targeting multiple antigens, MT-601 is designed to address patients who have relapsed after or are not candidates for CAR-T cell therapies.
Geoffrey Shouse, D.O., Ph.D., the principal investigator at City of Hope, noted that despite advances in LBCL treatment, patients who relapse following CAR-T therapy continue to face limited treatment Options and challenging clinical outcomes.
Why Is Non-Dilutive Funding Significant?
The $16.2 million CPRIT grant represents non-dilutive funding, meaning it does not require the company to issue additional shares. For a clinical-stage company, this type of funding can extend cash runway while advancing clinical programs. The award builds on previously secured NIH SBIR program funding for Phase 1 development.






Please wait processing your request...